Sumant S. Kulkarni

Allergan PLC (NYSE: AGN) shares are down 5 percent in the last three months, while shares of Pfizer Inc. (NYSE: PFE) have declined 8 percent over the same period. BofA Merrill Lynch’s Sumant S. Kulkarni maintained a Buy rating on Allergen, with a price objective of $385. Even if the...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) have declined more than 33 percent in the past  month, despite reaching a high of $262.52 on August 5. Sumant S. Kulkarni of Bank of America Merrill Lynch has reinitiated coverage of the company with a Buy rating and price...

In a report published on Thursday, Bank of America Merrill Lynch analyst Sumant S. Kulkarni maintained a Buy rating on Actavis plc (NYSE: ACT), while raising the price target to $350. "While early, ACT appears confident in its progress of the integration of Allergan, and we believe investors who...

Bank of America commented on Mylan NV (NASDAQ: MYL) Wednesday and maintained a Buy rating with a $69 price target. Analysts led by Sumant S. Kulkarni noted that it would take some time to work through the financial and valuation implications of Mylan’s proposed offer to acquire Perrigo...

In a report published Monday, Bank of America analyst Sumant S. Kulkarni reiterated a Buy rating and $68.00 price target on Mylan Inc (NASDAQ: MYL). In the report, Bank of America noted, “With significant acquisitions, MYL transformed itself from a US-only, generic-only story into a global,...

In a report published Tuesday, Bank of America analyst Sumant S. Kulkarni reiterated an Underperform rating on Impax Laboratories (NASDAQ: IPXL), and raised the price target from $27.00 to $28.00. In the report, Bank of America noted, “We are raising our DCF-based price objective from $27 to $28...

In a report published Tuesday, Bank of America analyst Sumant S. Kulkarni reiterated a Buy rating on Actavis plc (NYSE: ACT), and raised the price target from $246.00 to 254.00. In the report, Bank of America noted, “We like ACT's business mix (brands/generics/biosimilars), geographic footprint,...

In a report published Friday, Bank of America analyst Sumant S. Kulkarni downgraded the rating on Sagent Pharmaceuticals (NASDAQ: SGNT) from Buy to Neutral, but raised the price target from $25.00 to $28.00. In the report, Bank of America noted, “We remain constructive on SGNT over the longer term...

In a report published Tuesday, Bank of America analyst Sumant S. Kulkarni reiterated a Buy rating on Mylan (NASDAQ: MYL), and raised the price target from $62.00 to $67.00. In the report, Bank of America noted, “MYL announced that it is buying Abbott's specialty branded/generic business in the non-...

In a report published Thursday, Bank of America analyst Sumant S. Kulkarni reiterated a Buy rating on Akorn (NASDAQ: AKRX), and raised the price target from $28.00 to $33.00. In the report, Bank of America noted, “We continue to like AKRX's positioning as a niche player in ophthalmology, generic...

In a report published Thursday, Bank of America analyst Sumant S. Kulkarni reiterated a Buy rating on Akorn (NASDAQ: AKRX), and raised the price target from $18.00 to $21.00. In the report, Bank of America noted, “On 8/27, AKRX announced that it is buying Hi-Tech (HITK, which we also cover) for $...